Correlation Between Crispr Therapeutics and Monte Rosa

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Monte Rosa at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Monte Rosa into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crispr Therapeutics AG and Monte Rosa Therapeutics, you can compare the effects of market volatilities on Crispr Therapeutics and Monte Rosa and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Monte Rosa. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Monte Rosa.

Diversification Opportunities for Crispr Therapeutics and Monte Rosa

0.65
  Correlation Coefficient

Poor diversification

The 3 months correlation between Crispr and Monte is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Monte Rosa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monte Rosa Therapeutics and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Monte Rosa. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monte Rosa Therapeutics has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Monte Rosa go up and down completely randomly.

Pair Corralation between Crispr Therapeutics and Monte Rosa

Given the investment horizon of 90 days Crispr Therapeutics AG is expected to generate 1.05 times more return on investment than Monte Rosa. However, Crispr Therapeutics is 1.05 times more volatile than Monte Rosa Therapeutics. It trades about 0.17 of its potential returns per unit of risk. Monte Rosa Therapeutics is currently generating about 0.09 per unit of risk. If you would invest  3,723  in Crispr Therapeutics AG on May 28, 2025 and sell it today you would earn a total of  1,690  from holding Crispr Therapeutics AG or generate 45.39% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Crispr Therapeutics AG  vs.  Monte Rosa Therapeutics

 Performance 
       Timeline  
Crispr Therapeutics 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Crispr Therapeutics AG are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Crispr Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.
Monte Rosa Therapeutics 

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Monte Rosa Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Monte Rosa exhibited solid returns over the last few months and may actually be approaching a breakup point.

Crispr Therapeutics and Monte Rosa Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Crispr Therapeutics and Monte Rosa

The main advantage of trading using opposite Crispr Therapeutics and Monte Rosa positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Monte Rosa can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monte Rosa will offset losses from the drop in Monte Rosa's long position.
The idea behind Crispr Therapeutics AG and Monte Rosa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Complementary Tools

Share Portfolio
Track or share privately all of your investments from the convenience of any device
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum